- Home
- FCAP vs CTOR Comparison
FCAP vs CTOR Comparison
Compare FCAP & CTOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCAP
- CTOR
- Stock Information
- Founded
- FCAP 1891
- CTOR 2021
- Country
- FCAP United States
- CTOR United States
- Employees
- FCAP N/A
- CTOR N/A
- Industry
- FCAP Savings Institutions
- CTOR
- Sector
- FCAP Finance
- CTOR
- Exchange
- FCAP Nasdaq
- CTOR NYSE
- Market Cap
- FCAP 102.2M
- CTOR 89.9M
- IPO Year
- FCAP 1999
- CTOR N/A
- Fundamental
- Price
- FCAP $30.86
- CTOR $1.27
- Analyst Decision
- FCAP
- CTOR Strong Buy
- Analyst Count
- FCAP 0
- CTOR 2
- Target Price
- FCAP N/A
- CTOR $4.50
- AVG Volume (30 Days)
- FCAP 3.1K
- CTOR 171.0K
- Earning Date
- FCAP 01-28-2025
- CTOR 02-21-2025
- Dividend Yield
- FCAP 3.76%
- CTOR N/A
- EPS Growth
- FCAP N/A
- CTOR N/A
- EPS
- FCAP 3.52
- CTOR N/A
- Revenue
- FCAP $41,072,000.00
- CTOR N/A
- Revenue This Year
- FCAP N/A
- CTOR N/A
- Revenue Next Year
- FCAP N/A
- CTOR N/A
- P/E Ratio
- FCAP $8.77
- CTOR N/A
- Revenue Growth
- FCAP N/A
- CTOR N/A
- 52 Week Low
- FCAP $30.86
- CTOR $0.85
- 52 Week High
- FCAP $38.00
- CTOR $49.00
- Technical
- Relative Strength Index (RSI)
- FCAP 41.92
- CTOR N/A
- Support Level
- FCAP $30.49
- CTOR N/A
- Resistance Level
- FCAP $32.38
- CTOR N/A
- Average True Range (ATR)
- FCAP 0.84
- CTOR 0.00
- MACD
- FCAP -0.06
- CTOR 0.00
- Stochastic Oscillator
- FCAP 14.74
- CTOR 0.00
About FCAP First Capital Inc.
First Capital Inc is the financial holding company of First Harrison Bank. Through its subsidiary, it operates as a federally-chartered savings bank that provides banking services to individuals and business customers across locations in America. The bank offers various loans which include residential loans, construction loans, commercial real estate loans and commercial business loans. It also provides consumer loans such as home equity and second mortgage loans, and automobile and truck loans.
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.